Current Insights, Advantages and Challenges of Small Molecule Glucagon ...
By Eder Luna Ceron, Sparsha Duvuru Reddy & 4 more. The article discusses the advancement of orally available small-molecule GLP-1 receptor agonists (GLP-1RAs) in diabetes management, improving glycemic control, weight loss, and patient adherence while addressing cardiovascular and renal comorbidities.
Traditionally, GLP-1RAs require subcutaneous injection, presenting challenges in patient adherence and limiting combination therapy options. Recent advancements have introduced orally available small-molecule GLP-1RAs, which retain the physiological benefits of peptide-based GLP-1RAs, such as promoting insulin secretion, reducing appetite, and ...
PDF Current Insights, Advantages and Challenges of Small Molecule Glucagon ...
Current Insights , Advantages and Challenges of Small Molecule Glucagon -like Peptide 1 Receptor Agonists: A Scoping Review Eder Luna Ceron1, Sparsha Duvuru Reddy1, Lakshmi Kattamuri1, Durga Mounika Muvva1, Luis Chozet2, Tamis Bright2
The glucagon -like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types ...
Current Insights, Advantages and Challenges of Small Molecule Glucagon ...
A narrative review focuses on the pharmacodynamic profiles and the current progress in clinical and preclinical research on small-molecule GLP-1R agonists, indicating that this class of agents represents a compelling therapeutic alternative with the potential to reshape the treatment for metabolic disorders. Expand
The emergence of novel pharmacological agents, particularly glucagon -like peptide-1 receptor agonists (GLP-1RAs), has revolutionized T2DM management by addressing glycemic control and comorbidities such as cardiovascular and renal diseases.
Current Insights, Advantages and Challenges of Small Molecule Glucagon ...
Type 2 diabetes mellitus (T2DM) is a prevalent chronic condition with significant morbidity and mortality, largely due to its vascular complications. The emergence of novel pharmacological agents, particularly glucagon -like peptide-1 receptor agonists (GLP-1RAs), has revolutionized T2DM management by addressing glycemic control and comorbidities such as cardiovascular and renal diseases ...
Small-molecule glucagon -like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical binding orthosteric sites within the GLP-1 receptor transmembrane domain, enabling selective G protein ...
A novel approach to exploit Small
Small-molecule glucagon -like peptide-1 receptor (GLP-1R) agonists are recognized as promising therapeutics for type 2 diabetes mellitus (T2DM) and obesity. Danuglipron, an investigational small-molecule agonist, has demonstrated high efficacy in clinical trials. However, further development of danuglipron is challenged by a high rate of gastrointestinal adverse events. While these effects may ...
Key Numbers How They Did This Scoping review of the preclinical and clinical literature on small molecule (non-peptide) GLP-1 receptor agonists. The review examined the pharmacological profiles, preclinical efficacy data, clinical trial progress, and comparative advantages versus peptide-based GLP-1 receptor agonists for type 2 diabetes management.